Published in Am J Pathol on May 01, 2011
ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res (2011) 2.71
Integration of genomic data enables selective discovery of breast cancer drivers. Cell (2014) 1.11
Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. Int J Gynecol Pathol (2012) 1.02
Epigenomic regulation of oncogenesis by chromatin remodeling. Oncogene (2016) 0.97
RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance. Cancer Res (2014) 0.89
Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. J Pathol (2013) 0.89
High RSF-1 expression correlates with poor prognosis in patients with gastric adenocarcinoma. Int J Clin Exp Pathol (2012) 0.86
Prognostic value of rsf-1/hbxap in human solid tumors: a meta-analysis of cohort studies. Int J Clin Exp Med (2015) 0.80
ATP-dependent chromatin remodeling complexes as novel targets for cancer therapy. Adv Cancer Res (2014) 0.80
Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer. Int J Clin Exp Pathol (2014) 0.77
RSF1 regulates the proliferation and paclitaxel resistance via modulating NF-κB signaling pathway in nasopharyngeal carcinoma. J Cancer (2017) 0.75
Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy. Int J Mol Sci (2017) 0.75
Overexpression of Rsf-1 correlates with poor survival and promotes invasion in non-small cell lung cancer. Virchows Arch (2017) 0.75
Dissecting the regulatory circuitry of a eukaryotic genome. Cell (1998) 23.62
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
The World Oral Health Report 2003: continuous improvement of oral health in the 21st century--the approach of the WHO Global Oral Health Programme. Community Dent Oral Epidemiol (2003) 8.86
Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem (1998) 8.86
Global epidemiology of oral and oropharyngeal cancer. Oral Oncol (2008) 8.00
Ordered recruitment of transcription and chromatin remodeling factors to a cell cycle- and developmentally regulated promoter. Cell (1999) 6.83
ATP-dependent chromatin-remodeling complexes. Mol Cell Biol (2000) 5.07
The SWI/SNF complex and cancer. Oncogene (2009) 5.05
Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst (1998) 5.05
c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet (1999) 2.95
BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell (2000) 2.94
WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity. Nature (2008) 2.86
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
SWI/SNF chromatin remodeling and cancer. Curr Opin Genet Dev (2002) 2.00
Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer (2007) 1.99
The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis (2008) 1.92
When the SWI/SNF complex remodels...the cell cycle. Oncogene (2001) 1.79
Amplification of oncogenes in human cancer cells. Bioessays (1998) 1.70
Amplicon profiles in ovarian serous carcinomas. Int J Cancer (2007) 1.70
Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol (2006) 1.69
A YY1-INO80 complex regulates genomic stability through homologous recombination-based repair. Nat Struct Mol Biol (2007) 1.68
Chromatin remodeling and cancer, Part II: ATP-dependent chromatin remodeling. Trends Mol Med (2007) 1.59
Functional analysis of the subunits of the chromatin assembly factor RSF. Mol Cell Biol (2003) 1.56
A role for the yeast SWI/SNF complex in DNA replication. Nucleic Acids Res (1999) 1.51
Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res (2009) 1.36
Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer. Epigenetics (2008) 1.24
Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res (2009) 1.20
Chromatin remodeling: why it is important in cancer. Oncogene (2001) 1.19
Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. Hum Pathol (2006) 1.18
Chromatin-remodelling mechanisms in cancer. Mutat Res (2008) 1.17
The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. Cancer Res (2008) 1.16
Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. J Biol Chem (2010) 1.10
Proliferation-associated SNF2-like gene (PASG): a SNF2 family member altered in leukemia. Cancer Res (2000) 1.07
Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol (2006) 1.00
Chromatin remodeling factors and DNA replication. Prog Mol Subcell Biol (2005) 0.95
Frequent cyclin D1 gene amplification and protein overexpression in oral epithelial dysplasias. Oral Oncol (2001) 0.94
Functional interaction between nuclear matrix-associated HBXAP and NF-kappaB. Exp Cell Res (2004) 0.92
ATP-dependent chromatin remodeling enzymes and their various roles in cell cycle control. Front Biosci (2008) 0.84
Five SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin (SMARC) genes are dispersed in the human genome. Genomics (1998) 0.84
Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma. Int J Gynecol Pathol (2011) 0.82
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 7.27
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
Ovarian cancer. Annu Rev Pathol (2009) 4.92
Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67
Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat Genet (2011) 4.50
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell (2007) 4.48
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol (2009) 3.90
Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell (2005) 3.89
The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci U S A (2002) 3.46
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35
Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol (2008) 3.22
Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res (2007) 3.07
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol (2009) 2.94
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol (2005) 2.83
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell (2013) 2.81
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther (2006) 2.76
ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res (2011) 2.71
Meta-analysis identifies common variants associated with body mass index in east Asians. Nat Genet (2012) 2.70
Notch3 gene amplification in ovarian cancer. Cancer Res (2006) 2.66
Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol (2010) 2.65
Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol (2008) 2.60
MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med (2013) 2.58
Three classes of genes mutated in colorectal cancers with chromosomal instability. Cancer Res (2004) 2.51
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell (2012) 2.30
Variants in ADCY5 and near CCNL1 are associated with fetal growth and birth weight. Nat Genet (2010) 2.30
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
Ethylene glycol induces calcium oxalate crystal deposition in Malpighian tubules: a Drosophila model for nephrolithiasis/urolithiasis. Kidney Int (2011) 2.28
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol (2012) 2.27
Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res (2008) 2.26
Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res (2009) 2.25
Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol (2002) 2.18
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
Long contiguous stretches of homozygosity in the human genome. Hum Mutat (2006) 2.07
Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. Nat Genet (2012) 2.05
Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol (2011) 2.03
The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell (2012) 2.02
Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer (2008) 2.01
TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol (2011) 1.94
Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst (2002) 1.90
Identifying tumor origin using a gene expression-based classification map. Cancer Res (2003) 1.78
iSMART: an integrated cloud computing web server for traditional Chinese medicine for online virtual screening, de novo evolution and drug design. J Biomol Struct Dyn (2011) 1.72
Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med (2002) 1.72
Body mass index trajectory classes and incident asthma in childhood: results from 8 European Birth Cohorts--a Global Allergy and Asthma European Network initiative. J Allergy Clin Immunol (2013) 1.71
DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res (2010) 1.71
Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol (2009) 1.71
Amplicon profiles in ovarian serous carcinomas. Int J Cancer (2007) 1.70
The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol (2007) 1.70
Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004. Am J Med Genet A (2009) 1.67
Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res (2004) 1.66
Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-a longitudinal study. Int J Radiat Oncol Biol Phys (2008) 1.64
Light response of retinal ON bipolar cells requires a specific splice variant of Galpha(o). J Neurosci (2002) 1.62
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res (2006) 1.62
Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. Nat Genet (2011) 1.60
Increased plasma DNA integrity in cancer patients. Cancer Res (2003) 1.59
Digital karyotyping. Nat Protoc (2007) 1.58
Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol (2003) 1.58
Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res (2008) 1.56
Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics (2009) 1.56
Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol (2011) 1.56
Principle and applications of digital PCR. Expert Rev Mol Diagn (2004) 1.55
Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res (2005) 1.55
Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest (2011) 1.54
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci U S A (2006) 1.52
Mesenchymal stem cell insights: prospects in cardiovascular therapy. Cell Transplant (2014) 1.50
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol (2010) 1.45